Certain ergot peptide alkaloids administered to the nasal mucosa
US4462983A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 8, 1981 |
| Grant date | Jul 31, 1984 |
| Priority date | — |
| Expiry date | Dec 8, 2001 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01D2207/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a nasal or pulmonary pharmaceutical composition comprising as active agent a compound of formula I, ##STR1## wherein R.sub.1 is hydrogen or halogen, PA1 R.sub.2 is hydrogen or alkyl of 1 to 4 carbon atoms, either (i) PA1 R.sub.3 is isopropyl, sec-butyl, or isobutyl, PA1 R.sub.4 methyl, ethyl or isopropyl and PA1 R.sub.5 is hydrogen and R.sub.6 is hydrogen or methoxy PA1 or R.sub.5 and R.sub.6 are together a single bond, or (ii) PA1 R.sub.3 is benzyl, R.sub.4 is methyl, R.sub.5 is hydrogen and R.sub.6 is hydrogen or methoxy, or (III) dihydroergocristine, in association with a pharmaceutically acceptable carrier or diluent, adapted for nasal or pulmonary administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.